Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor alpha mRNA is the messenger RNA transcribed from the TNF gene, which is primarily expressed in immune cells such as macrophages. It encodes the cytokine TNF-α, a central mediator of inflammation and immune responses. The stability and translation of TNF-α mRNA are tightly regulated by sequence motifs, especially AU-rich elements in the 3' untranslated region, which bind proteins that promote rapid mRNA degradation in resting cells, and increase mRNA stability in activated cells. Therapeutically, TNF-α mRNA is rarely the direct target; instead, current drugs predominantly inhibit the TNF-α protein. However, research efforts occasionally focus on suppressing TNF-α mRNA using RNA interference or antisense molecules, though these are not standard clinical approaches.
Inhibition of TNF-α mRNA leads to decreased TNF-α protein synthesis, reducing inflammation or immune response
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor alpha mRNA (TNF-α mRNA).